alexa Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes.
Surgery

Surgery

Medical & Surgical Urology

Author(s): SnowLisy DC, Campbell SC, Gill IS, Hernandez AV, Fergany A,

Abstract Share this page

Abstract BACKGROUND: Extended oncologic outcomes after minimally invasive cystectomy have not been previously reported. OBJECTIVE: To report outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC) for bladder cancer (BCa) at up to 12-yr follow-up. DESIGN, SETTING, AND PARTICIPANTS: All 121 patients undergoing RARC or LRC for BCa between December 1999 and September 2008 at a tertiary referral center were retrospectively evaluated from a prospectively maintained database. INTERVENTION: RARC or LRC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary end points were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) calculated using Kaplan-Meier curves. Secondary end points were survival analysis by number of lymph nodes (LNs) and type of procedure. Surgical outcomes, including complications, were analyzed. RESULTS AND LIMITATIONS: Most tumors were muscle invasive (≥ pT2; n=81; 67\%) urothelial carcinomas (n=102; 84\%). Extended LN dissection was performed in 98 patients (81\%), with a median of 14 nodes removed (interquartile range [IQR]: 8-18). Twenty-four patients (20\%) had node-positive disease (N1: 10 [8\%]; N2: 14 [12\%]). Eight patients (6.6\%) had positive soft tissue margins. Median follow-up was 5.5 yr (mean: 5.9; IQR: 4.2-8.2; range: 0.13-12.1). At last follow-up, 58 patients (48\%) had no evidence of disease, 3 (2\%) were alive with recurrence, 59 (49\%) had died, and status was unknown in 1. Twenty-eight patients (23\%) died from cancer-specific causes, 20 (17\%) from unrelated causes, and 11 (9\%) from unknown causes. The 10-yr actuarial OS, CSS, and RFS rates were 35\%, 63\%, and 54\%, respectively. At last follow-up, OS for pT0, pTis/a, pT1, pT2, and pT3 versus pT4 was 67\%, 73\%, 53\%, 50\%, and 16\% versus 0\%, respectively (p=0.02). At last follow-up, CSS for pT0, pTis/a, pT1, pT2, and pT3 versus pT4 was 100\%, 91\%, 74\%, 77\%, and 56\% versus 0\%, respectively (p=0.03). CONCLUSIONS: The longest oncologic outcomes following RARC and LRC for BCa reported demonstrates results similar to those reported for open RC. Continued analysis and direct randomized comparison between techniques is necessary. Copyright © 2013. Published by Elsevier B.V. This article was published in Eur Urol and referenced in Medical & Surgical Urology

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords